Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.
In the latest in a string of post-Shire divestments designed to hone its global focus on core therapeutic areas and innovative products, Takeda Pharmaceutical has reached an agreement to divest a portfolio of 18 selected over-the-counter (OTC) and prescription pharmaceutical products sold exclusively in the Asia-Pacific region to Celltrion.
The major South Korean group, which is now focused mainly on biologics, will pay $266m upfront in cash and up...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
